Ã¦REVIEW ARTICLE

Rheumatoid arthritis and
periodontitis  inï¬‚ammatory and
infectious connections. Review of the
literature

G. Rutger Persson*

Department of Periodontics and Department of Oral Medicine, University of Washington, Seattle, WA,
USA; Oral Health Sciences, University of Kristianstad, Kristianstad, Sweden; and Department of
Periodontology, University of Bern, Bern, Switzerland

An association between oral disease/periodontitis and rheumatoid arthritis (RA) has been considered since
the early 1820s. The early treatment was tooth eradication. Epidemiological studies suggest that the
prevalence of RA and periodontitis may be similar and about 5% of the population are aged 50 years or older.
RA is considered as an autoimmune disease whereas periodontitis has an infectious etiology with a complex
inflammatory response. Both diseases are chronic and may present with bursts of disease activity. Association
studies have suggested odds ratios of having RA and periodontitis varying from 1.8:1 (95% CI: 1.03.2, NS)
to 8:1 (95% CI: 2.922.1, pB0.001). Genetic factors are driving the host responses in both RA and
periodontitis. Tumor necrosis factor-a, a proinflammatory cytokine, regulates a cascade of inflammatory
events in both RA and periodontitis. Porphyromonas gingivalis is a common pathogen in periodontal
infection. P. gingivalis has also been identified in synovial fluid. The specific abilities of P. gingivalis to
citrullinate host peptides by proteolytic cleavage at Arg-X peptide bonds by arginine gingipains can induce
autoimmune responses in RA through development of anticyclic citrullinated peptide antibodies. In addition,
P. gingivalis carries heat shock proteins (HSPs) that may also trigger autoimmune responses in subjects with
RA. Data suggest that periodontal therapies combined with routine RA treatments further improve
RA status.
Conclusions: Periodontal infection (P. gingivalis) carries a unique risk for development of autoimmune
antibodies associated with RA. Patients with RA have either lost many teeth or usually have severe
periodontitis. Additional research, both in regards to basic mechanisms as well as clinical studies, are
necessary before it can be said that there are causative links between RA and periodontitis. Cross-disciplinary
research in well-defined populations should be performed to further enhance knowledge and develop clinical
strategies how to coordinate therapy and risk assessments of RA and periodontitis.

Keywords: rheumatoid arthritis; periodontitis; bacteria; inï¬‚ammation; Porphyromonas gingivalis; citrullination; genetics;
review

Received: 6 November 2011; Revised: 23 January 2012; Accepted: 23 January 2012; Published: 13 February 2012

During the last 200 years, a possible association

between rheumatoid arthritis (RA) and oral
disease (periodontitis) has been debated. Recent
research with focus on inflammation in relation to
infection by Porphyromonas gingivalis has identified an
infection-immune response as one explanatory factor to
why subjects with periodontitis may develop RA. Experi-
ences from anti-inflammatory therapies in the manage-
ment of RA may be useful also in the management of
periodontitis. In the present review, studies on the

Approximately 1% of

associations, etiological co-factors, and effects of therapy
in patients with RA and periodontitis will be discussed.
the total world population
suffers from RA. The prevalence of RA increases with
age and is three times more prevalent in women with 5%
of women aged older than 55 years being affected (1, 2).
RA is an autoimmune condition and diagnosed as
chronic inflammatory polyarthritis when five or more
joints are affected (3). The progression of RA can be (1)
monocyclic (one single episode with or without therapy

Journal of Oral Microbiology 2012. # 2012 G. Rutger Persson. This is an Open Access article distributed under the terms of the Creative Commons Attribution-
Noncommercial 3.0 Unported License (http://creativecommons.org/licenses/by-nc/3.0/), permitting all non-commercial use, distribution, and reproduction in any
Citation: Journal of Oral Microbiology 2012, 4: 11829 - DOI: 10.3402/jom.v4i0.11829
medium, provided the original work is properly cited.

1

(page number not for citation purpose)

G. Rutger Persson

ending within 5 years and not reoccurring), (2) polycyclic
(fluctuating with several episodes of disease activity, and
(3) progressive (continuing to increase in severity and
unremitting). Clinically, RA is currently diagnosed ac-
cording to the 2010 American College of Rheumatology
(ACR) and the European League Against Rheumatism
(EULAR) classification that includes nine criteria (4)
[http://www.rheumatology.org/practice/clinical/classification/
ra/ra_2010.asp].

The diagnosis of RA is based on the clinical history,
physical examination, blood count [i.e. eosinophil sedi-
mentation rate, serum C-reactive protein (CRP), and
immunoglobulin rheumatoid factor (RF)]. In addition,
imaging methods [radiographs, magnetic resonance im-
aging (MRI), computer imaging methods (CAT and bone
scans)] are used to assess various joints. RA typically
manifests with signs of inflammation, with the affected
joints being swollen, warm, painful, and stiff. The
inflammatory activity leads to tendon tethering, erosion,
and destruction of the joint surface. This results in joint
deformity impairing the range of movement and is often
associated with pain.

The etiology of RA is not well understood. Most likely,
there is a combination of genetic (including epigenetics 
changes in gene expression or cellular phenotype caused
by other mechanisms than changes in the underlying
DNA sequence), environmental, hormonal, and infec-
tious co-factors. RA has, in addition to periodontitis, also
been associated with other diseases such as heart diseases,
lung diseases, gastrointestinal diseases (including Morbus
Crohn), osteoporosis, and skin diseases.

Periodontitis is a common disease affecting between 3
and 60% (depending on the criteria used to define
periodontitis) (5). The current differential criteria for
periodontal diseases include gingivitis, chronic period-
ontitis, aggressive periodontitis, periodontitis as a man-
ifestation of systemic diseases, necrotizing periodontal
diseases, abscesses of the periodontium, and periodontitis
associated with endodontic lesions (6). Since the late
1990s, there has been an increasing interest in other
diseases that can be associated with periodontitis. From a
historical perspective, RA has been associated with
periodontitis since the early 19th century when Benjamin
Rush (American physician and politician) identified that
total tooth eradication was a cure for â€˜rheumaâ€™. Therapy
with extraction of all teeth was common in the early 20th
century, promoting the focal infection theory and the
values of full mouth tooth eradication. This continued to
be the praxis in many countries until Cecil and coworkers
in the late 1930s concluded that tooth eradication was not
a solution to the treatment of RA. In 1952, the American
Medical Association clarified that this practice was not
based on scientific evidence and that tooth eradication
should not be considered as a treatment approach to
reduce the severity, or symptoms of RA (7).

To what extent the eradication of all teeth in subjects
with advanced periodontitis has a systemic positive
impact continues to be an open question. The local
infection-driven inflammatory process of the periodon-
tium has,
in general, been proposed as one possible
mechanism triggering systemic inflammatory processes
or spread of infection (8, 9). Taylor et al. (10) identified
that if non-smoking subjects with severe periodontitis
had all their teeth extracted, a significant decrease in
serum CRP, plasminogen activator inhibitor-1, fibrino-
gen, WBC, and platelet counts would occur. Thus, it
appears that eradication of an oral source of infection has
systemic effects resulting in a reduction of systemic
inflammation. In addition, others have shown that non-
surgical periodontal therapy can result in not only an
immediate severe increase in serum CRP levels but also
that CRP values decrease to pretreatment values within
30 days (11). Bacteremia with an oral bacterial origin
may, in part, explain the increase in serum markers of
inflammation. Both observations can be used to accept
the proof of principle that periodontitis is not an isolated
local disease. Periodontitis is a disease with involvement
of soft and hard tissues, a complex infectious etiology
with significant inflammatory â€˜systemicâ€™ consequences.

The periodontium, a bacterial habitat and a
systemic disease in the susceptible host
Consistent with RA, a cyclic nature of chronic period-
ontitis has been identified (12, 13). The infectious
etiology of periodontitis is well established (not refer-
enced here). The subgingival biofilm may be in flux and
constantly respond to nutritional and other challenges.
Data suggest that the subgingival microbiological profile
is also dependent on gene clusters, and it
is not
necessarily the periodontal probing pocket depth that
defines the microbiological profile. Data suggest an
important genetic impact on the infectious susceptibility
in subjects with periodontitis (14). The periodontal
â€˜nicheâ€™ harbors a uniquely broad spectrum of bacteria
(15, 16).

A single pathogen fulfilling the DNA sequence-based
identification of pathogens as required by the modified
Henle-Koch postulate (17) has not been identified for the
periodontal
infection. In part, the criteria have been
fulfilled in that it is possible to infect the periodontium
with P. gingivalis (18) and that immunization against this
pathogen can control the infection in the same animal
model (19, 20). Data have also shown that purified
porphypains from P. gingivalis and used as a vaccine
provides protection against periodontitis in a non-human
primate model (21). This may be an important observa-
tion, especially in the relation to citrullination (see below)
and a possibility to control P. gingivalis-induced citrulli-
nation. Many of the bacterial species considered as
putative pathogens and identified in the oral cavity can

2

(page number not for citation purpose)

Citation: Journal of Oral Microbiology 2012, 4: 11829 - DOI: 10.3402/jom.v4i0.11829

also be found at other locations. This may be a
consequence of host susceptibility, a natural habitat for
such bacteria, or infectious etiology of disease (i.e.
2225). The effects of bacteremia from oral sources
have been difficult to study.

(SNPs) and risk of

Genetics in periodontitis and rheumatoid
arthritis
Genome-wide association studies have identified replic-
able, genetic associations between common single nucleo-
tide polymorphisms
common
autoimmune and inflammatory (immune-mediated) dis-
eases such as RA (26). In recent years, several studies
have also been published assessing genetic factors in
periodontitis. Due to the lack of power and study design
flaws almost, all genetic variants associated with period-
ontitis that have been published are, therefore, question-
able (27). Notwithstanding, genetic factors are driving
immune responses in general, and there can be no doubt
that the susceptibility to periodontitis can be derived
from genetic mechanisms. The most appropriate ap-
proach to studies of genetic factors in periodontitis
should be a cross-disciplinary medical study approach.

The literature on the relationship between genetic
factors and RA is extensive. Studies have yielded novel
genetic loci underlying several common diseases, includ-
ing RA. Thus, â€˜leukocyte activation and differentiationâ€™,
â€˜pattern-recognition receptor signaling pathwayâ€™, and
â€˜chemokines and their receptorsâ€™ can explain mutation-
induced RA (28). Research investigating the relationship
between polymorphisms and disease has demonstrated
strong links between susceptibility to RA and genetic
factors. Different genetic markers have found human
leukocyte antigen (HLA) genetic factors as explanatory
to early onset of RA (29). In addition, and due to the
aging process and immunosenescence, telomere erosion
appears to proceed more rapidly in patients with RA than
in healthy control subjects, resulting in an early onset of
the disease in RA susceptible individuals (30).

Environmental factors can cause reversible and non-
reversible genetic changes. Heritable changes in gene
expression or cellular phenotype caused by mechanisms
other than changes in the underlying DNA sequence are
studied through epigenetics. Epigenetic changes occur
without a direct change in the genetic sequence and may
be reversible. Epigenetic alterations are sources of
potential genetic defects resulting in gene malfunctions
and may be linked to both RA (31) and periodontitis
(32). Reduced synovial expression of histone deacetylases
(HDACs) is proposed to contribute to pathology in RA
(33). Epigenetic changes have been linked to the X
chromosome. This may, partly, explain the gender
difference in RA prevalence. Not only gender, viral
infection, hormones, and geography but also nutrition
and chemicals have been identified through epigenetics.

Rheumatoid arthritis and periodontitis

Both intrinsic to the DNA sequence (polymorphism and
mutations) and extrinsic to the DNA sequence (DNA
methylation) stable and heritable changes in gene expres-
sion without changes in the genetic code can occur. There
are merging data suggesting that dietary factors, such as
micro-nutrients and non-nutrient dietary components,
can modify epigenetic marks (34).

Rheumatoid arthritis and infection in the
susceptible host
A combination of environmental and genetic factors with
antibodies directed against cyclic citrullinated peptide
(anti-CCP) has been associated with the onset of
RA (29).

Citrullination or deamination is the term used for a
genetic modification of the amino acid arginine in a
protein into the amino acid citrulline and caused by
enzymatic activity through peptidylarginine deaminases
(PADs). Data have shown that anti-CCP antibody in
addition to the RF predate the onset of RA with anti-
CCP antibody levels having the highest predictive value
(35).

In 2004, Rosenstein et al. (36) introduced the hypoth-
esis that P. gingivalis, which is the sole microorganism
documented to express PAD, would allow individuals
with periodontitis to be exposed to citrullinated antigens,
predisposing to development of anti-cyclic citrullinated
peptide (CCP) antibodies and to be at risk for RA.
Thus, P. gingivalis rapidly generates citrullinated host
peptides by proteolytic cleavage at Arg-X peptide bonds
by arginine gingipains,
followed by citrullination of
carboxy-terminal arginines by bacterial peptidylarginine
deiminase (37). Studies have shown that P. gingivalis
contains a range of endogenous citrullinated proteins that
are not present in other common oral pathogens (38).
The expression of citrullinated autoantigens in synovial
fluid indicates the important role of citrullination in RA
(39). Oral bacterial infection (P. gingivalis) may, therefore,
play a role in peptide citrullination and involved in loss of
self-tolerance and development of RA (40). Data suggest
that citrullinated proteins are also present in the gingiva
of patients with periodontitis (41). Immunization with
cysteine proteases purified from P. gingivalis against
periodontitis may, therefore, have significance also in
the prevention and management of RA through humoral
factors and with an impact on cytokine production and
control of infection and inflammation (21). There are few,
if any, other studies that have linked specific bacteria as
potentially causative bacteria in RA. Thus, P. gingivalis
may directly be linked to RA through citrullination and
induction of antipeptidyl citrulline antibodies reacting to
citrullinated human self-proteins (41). This may be the
most convincing evidence that a pathogen associated with
periodontitis has an impact in the development and
progression of another disease (RA). This concept may

Citation: Journal of Oral Microbiology 2012, 4: 11829 - DOI: 10.3402/jom.v4i0.11829

(page number not for citation purpose)

3

G. Rutger Persson

be more plausible than what has been suggested for the
impact of periodontal
i.e.
cardiovascular diseases.

infection in relation to,

been reported in cases with chronic periodontitis
(50). These findings are also consistent with in vitro
experiments (51).

Markers of inflammation in periodontitis and
rheumatoid arthritis
One of the conditions in RA has been identified as
synovitis. Synovitis is characterized by leukocyte infiltra-
tion, proliferation of fibroblast-like synoviocytes, osteo-
clast activation, presence of mast cells, B cells, and
characteristic CD4/CD8 ratio (4244). The synovial
fluid is
rich in proinflammatory cytokines. Several
interleukins (ILs) (i.e. IL-1, IL-6, IL-8, IL-15, and IL-
17) (45) as well as NF-kappaB ligand (RANKL) (46) can
be associated with RA. Similar proinflammatory cyto-
kines have also been associated with inflammation in
periodontitis (47).

The proinflammatory cytokine, tumor necrosis factor
(TNF)-a, is of special interest for the understanding of
immune responses in relation to a linkage between
RA and periodontitis. The literature on the effects of
elevated serum levels of TNF-a and the association
between TNF-a and RA is extensive (i.e. (48)). Due to
the fact that treatment with anti-TNF-a medication is
commonly used to control for the inflammatory process
in RA, such therapy may also be relevant
for the
management of periodontitis.

cascade,

TNF-a is released in response to lipopolysaccharide
and other bacterial byproducts. A local increase in TNF-
a concentration results in heat, swelling, redness, pain,
and loss of function. Elevated serum levels of TNF-a
induce production of CRP and promote the expression of
adhesion molecules on endothelial cells allowing neutro-
phil diapedesis and inducing IL-1 activation. Within the
cytokine
to
produce MMPs (stromelysin) with activation of collage-
nase, resulting in cartilage destruction. IL-1 is a chemoat-
tractant facilitating the migration of polymorphonuclear
cells into the synovial tissues. High levels of IL-1 also
cause increased production of nitric oxide killing of
IL-1 regulates NFkB-osteoprotegerin-
chondrocytes.
RANKL and induces osteoclast activation. These
inflammatory processes result in osteolysis in both RA
and periodontitis.

IL-1 stimulates

synoviocytes

In regard to proinflammatory cytokines and immune
responses in periodontitis, detailed information from an
extensive literature review is currently available (49). TNF-a
has been of interest in periodontal research as this pro-
inflammatory cytokine while TNF-a upregulates produc-
tion of prostaglandin E2 and matrix-metalloproteinases
(MMPs), causing osteoclast stimulation. This results
in bone resorption, a prominent pathogenic feature in
periodontitis. A higher expression of protease-activated
receptor-2 (PAR2), IL 1a, IL-6, IL-8, and TNF-a
at periodontal site where P. gingivalis is present has

Studiesontheassociationandexplanatoryvariables
tosupporttheperceptionofanassociationbetween
rheumatoid arthritis and periodontitis
Several studies on the association between RA have been
published. A summary of study designs and results
obtained from such studies are presented in a time-
sequential order (Table 1). There are few large cross-
sectional studies assessing the associations between RA
and periodontitis. Most studies have used the criteria for
RA defined by the ACR (53), and the criteria for
periodontitis defined by the American Association of
Periodontology. The studies presented in Table 1 were
identified through screening documents published in
peer-reviewed journals in the English language since
2001 and avoiding other review articles. The primary
focus was also on human studies.

Genetic factors have been identified for the association
between RA and periodontitis (55, 63, 67). Odds ratios
that subjects with RA have more frequently and with
more severe periodontitis varied between OR: 2.2:1 (52)
and OR: 8.1:1 (59), whereas one study found no
significant association (57). Periodontal disease severity
(OR: 2.1:1) was ranked as number three as a predictive
factor for RA with female gender (OR: 7:1) and smoking
(OR: 2.9:1) as the primary predictors (63). Other studies
have not assessed the likelihood of an association but
rather defined shared etiological factors or host response
mechanisms between RA and periodontitis.

One of the problems in assessing proinflammatory
factors in RA and periodontitis is that some studies
represent convenience studies where subjects at the time
of assessment were treated with a variety of common
medication against RA symptoms (see below). Thus, the
lack of higher TNF-a and CRP serum levels in subjects
with both RA and periodontitis may be explained by the
impact of anti-inflammatory routine RA medications (58,
61, 63, 67). Another problem with the studies identified
can be linked to the cross-sectional nature of study design
and that the chronicity of periodontitis and previous
treatments of periodontitis or RA were not accounted for.
In one well-controlled clinical casecontrol study (54)
study including hospitalized RA patients, analyzing the
frequency of different oral bacterial DNA species in
periodontal pocket samples, sera, and synovial fluids of
patients with RA and controls, the authors identified
variable bacterial DNA concentration of bacteria with
(most likely) an oral origin in synovial fluids and in
serum from the patients with RA. In one case series (62)
including 19 subjects
screening of
500 subjects with RA refractory subjects not responding
to disease modifying antirheumatic drugs (DMARDS)

remaining after

4

(page number not for citation purpose)

Citation: Journal of Oral Microbiology 2012, 4: 11829 - DOI: 10.3402/jom.v4i0.11829

C

i
t
a
t
i
o
n

:

J
o
u
r
n
a

l

o
f

O
r
a

l

i

M
c
r
o
b
o
o
g
y

i

l

2
0
1
2
,

4

:

1
1
8
2
9

-
D
O

I
:

1
0
.
3
4
0
2
/
j
o
m
.
v
4
0
.
1
1
8
2
9

i

(

p
a
g
e

n
u
m
b
e
r

n
o
t

f
o
r

c
i
t
a
t
i
o
n

p
u
r
p
o
s
e
)

5

Table 1. Selected studies assessing the association between periodontitis and rheumatoid arthritis

First author and
reference

General study design and

characteristics

Clinical data

Laboratory data

Findings

Conclusions/comments

PPD, CAL BOP,
panoramic radio-
graphy

CRP, ESR

Mercado et al.

Casecontrol clinical study.

(52)

RA defined by ACR criteria
(54), visual analog scale (VAS).
Periodontitis was defined as
mild, moderate, or severe.
65 consecutive cases with RA
and 65 matched healthy con-
trol subjects.
75% were women.

Moen et al. (54) Casecontrol clinical study

RA defined by ACR criteria (53)
16 subjects with RA; 14 sub-
jects with PsA; 9 control sub-
jects with osteoarthritis.

PPD, CAL, evi-
dence of alveolar
bone loss assessed
from radiographs;
HAQ; DAS28

CRP, WBC, platelet counts, IgG
conc.
Synovial fluid and serum analysis:
bacterial samples assessed by
DNA checkerboard (40 species).

Kobayashi

et al. (55)

Casecontrol clinical study
RA defined by ACR criteria (52)
Periodontitis: AAP criteria (6)
100 subjects with RA, 100
subjects with periodontitis,
100 healthy subjects.

Leksell et al. (56) Casecontrol study.

Subjects between 10 and 19
years
41 juvenile idiopathic arthritis
(JIA) on DMARDs.
41 control subjects.

Assessment of
BOP, PPD, CAL

IL 1 gene polymorphism was
assessed by PCR for IL1-1A
4845, IL-1B 3954, IL-1 RN
2041, and FcyR genes.

Serum RF, CRP, ESR, salivary flow
rate.

Plaque, calculus,
PPD, CAL, and
mucosal lesions
Dental radiographs.
Child Health As-
sessment Ques-
tionnaire Stanford
HAQ disability
index.

ESR higher in RAsubjects with severe
periodontitis (pB0.001). More tooth loss in
RA14 vs. 7 teeth (pB0.001). BOP and
plaque index (NS), more alveolar bone loss
in RA subjects (68% vs. 30%) (OR: 2.3,
95% CI: 1.1, 4.6, pB0.03). More severe
PPD in RA subjects (OR: 2.2, 95% CI:
0.9, 9.4, p0.07). Every 1 mg/l increase
in CRP increased the odds of severe
periodontitis (OR:1.1, 95% CI: 1.1, 1.2,
pB0.001)
A. naeslundii, E. nodatum, P. gingivalis, P.
nigrescens exclusively found in serum from
RA subjects.
Synovial fluids: oral bacteria in 14/16 RA,
17/14 PsA, and 9/9 OA subjects with
highest total counts in RA (pB0.001).
Bacteria in synovial fluid from RA and
PsA subjects: E. saburreum, P. micra,
A. israelii, S. noxia, P. acnes, C. showae,
T. forsythia, C. sputigena, L. buccalis,
P. intermedia
No correlation between serum CRP, WBC,
platelet counts, and oral bacteria.
Eighty-six per cent of RA subjects had
periodontitis, but milder form of period-
ontitis than the periodontitis non-RA con-
trol group.
The RA subjects had fewer remaining
teeth. A higher prevalence of RAsubjects
with the IL-1B3954 T allele had RA and
periodontitis.
68% JIA and 12% controls had pain when
opening the mouth. 12% JIA had intra-oral
ulcers. 32% JIA but none in control group
had increased PPD/IAsubjects on anti-
TNF-a had lower BOP scores.
Medications; anti-TNF-a, DMARD,
NSAIDs, and methotrexate.

An association between RA and
the severity of periodontitis was
demonstrated in regard to bone
loss.
Plaque and gingival conditions
were not related to dexterity loss
in RA.
The relationship between ESR
and periodontitis was unclear.
The study did not prove causality.

Bacterial DNA from a variety of
species can be found in synovial
fluid.
Higher counts of oral bacterial
DNA in synovial fluid than in
serum from RA subjects sug-
gest that synovial fluid may cap-
ture DNA from oral bacteria.

IL-1 and FcyR gene polymor-
phisms carry an increased risk for
RA and periodontitis. This may be
specific for Japanese.
Anticitrullin antibodies at higher
levels in subjects with RA and
severe periodontitis.

Children with JIA have more oral
ulcerations, more discomfort,
more plaque, BOP, and gingival
hyperplasia.
Children with JIA on anti-TNF-a
had less gingivitis.

R
h
e
u
m
a
t
o
d

i

a
r
t
h
r
i
t
i
s

a
n
d

p
e
r
i
o
d
o
n
t
i
t
i
s

6(

p
a
g
e

n
u
m
b
e
r

n
o
t

f
o
r

c
i
t
a
t
i
o
n

p
u
r
p
o
s
e
)

C

i
t
a
t
i
o
n

:

J
o
u
r
n
a

l

o
f

O
r
a

l

i

M
c
r
o
b
o
o
g
y

i

l

2
0
1
2
,

4

:

1
1
8
2
9

-

D
O

I
:

1
0
.
3
4
0
2
/
j
o
m
.
v
4
0
.
1
1
8
2
9

i

G

.

R
u
t
g
e
r

P
e
r
s
s
o
n

Table 1 (Continued)

First author and
reference

De Pablo et al.

(57)

Nilsson et al.

(58)

Pischon et al.

(59)

Btytkoglu et al.

(61)

Martinez-

Martinez et al.
(62)

General study design and

characteristics

Clinical data

Laboratory data

Findings

Conclusions/comments

Epidemiological study
(NHANES III).
RA defined by ACR criteria
(53).
Study included 103 (2.3%)
subjects with RA from a total of
44,461 subjects.
Case series clinical study.
RA defined by ACR criteria
(53).
Consecutive subjects with RA.
30 healthy control subjects.

Cross sectional clinical study
RA: defined by DAS28 (60),
HAQ
Periodontitis: mean
CAL  4.0 mm.
57 RA and 52 healthy control
subjects

Casecontrol clinical study.
RA defined by ACR criteria
(53). AAP criteria for
periodontitis (6).
23 RA and 17 RA- but with
periodontitis.
17 RA- and periodontally
healthy subjects.

Case series clinical study.
RA defined by ACR criteria
(53).
Subjects with refractory RA
and periodontitis 19 subjects.
Periodontitis defined as PPD
] 3 mm and CAL ] 2 mm at
10 sites.
All subjects on DMARDs, ster-
oids and NSAIDs.

Periodontal: CAL
and PPD

Serum CRP

Periodontal: CAL%
3 mm, PPD%
3 mm, BOP%

Peripheral blood: ESR, CRP
thrombocyte particle conc., RA
factor, TNF-a, IL-Ia, IL-1 b, IL-1ra,
PGE2, 5-HT serotonin

ESR, CRP IgG, IgM, RF,
antibodies to CCP (ELISA).

Periodontal: gingi-
val index, plaque
index, PPD, CAL.
Smoking, alcohol,
BMI

Periodontal: PPD,
CAL, gingival index.

Serum RA factor, ESR, CRP, gin-
gival fluid samples: ELISA: Il-1b,
PGE2, plasminogen inactivator
PAI-2 and plasminogen activator
t-PA.

Periodontal: PPD,
CAL

Synovial fluid samples and sub-
gingival crevicular fluid samples,
serum samples, PCR analysis of
A. actinomycetemcomitans,
P. gingivalis, P. intermedia,
P. nigrescens, T. denticola,
T. forsythia.

CRP values were higher in RA subjects.
OR: 1.8:1; 95% CI: 1.04, 3.2 (pB0.05).
Subjects with RA were more likely to be
edentulous (OR: 2.27, 95% 95% CI: 1.56,
3.31, pB0.05) and to have periodontitis
(OR: 1.82, 95% CI: 1.04, 3.20, pB0.05)
compared with non-RA subjects.
TNF-a was the only factor predictive of
dental factors. TNF-a was predictive of%
BOP (pB0.01).TNF-a was predictive of
PPD% (pB0.05). TNF-a was predictive
of% CAL (pB0.01). TNF-a differed by RA
status (pB0.001).
RA had on average 0.9 mm more CAL
(pB0.001), and 0.6 mmPPD
(pB0.001) BOP and PI (pB0.001). Ra
subjects had a 6-folds higher risk
for periodontitis (unadj.)
8.05 (95%CI: 2.9, 22.1, pB0.001) age adj.
OR: 8.1
(95% CI: 2.9, 22.4, pB0.001).
RA factor, ESR, and CRP values in
RA subjects did not differ by periodontal
diagnosis. No difference by any parameter
between RA/periodontitis and RA/peri-
odontitis t-PA total amounts and conc.
In RAand periodontitissubjects t-PA
total amounts were higher than in period-
ontitis  subjects.
PAI-2 levels, Il-1b, and PGE2 were similar
between RA and  control subjects with
or without periodontitis.
Detected in synovial fluid: P. intermedia
(89%); T. denticola (31.5%); P. gingivalis
(57.8%); P. nigrescens (21%); T. forsythia
(10%); A. actino. (15%).
Detected in GCF: P. intermedia (100%);
T. denticola (84.2%); P. gingivalis (78.9%);
P. nigrescens (68%); T. forsythia (52.6%);
A. actino. (21%).
Detected in serum: P. intermedia (73.6%);
T. denticola (21%); T. forsythia (31.5%);
P. gingivalis (42.1%).

Subjects with RA were more often
edentulous and did not attend
dental regularly and to have more
periodontitis if dentate.

Gingivitis and periodontitis are
related to high levels of circulating
TNF-a in subjects who are RA.

Subjects with RA have signifi-
cantly more CAL (periodontitis)
than non-RA subjects.
Oral hygiene may only partially
account for this association.

The coexistence of RA and peri-
odontitis does not seem to affect
clinical periodontal findings or
systemic markers of RA. The lack
of difference may be the result of
anti-inflammatory treatment of
RA subjects.

P. intermedia, P. gingivalis, and
T. denticola were the most pre-
valent species found in synovial
fluid.
Possibly, a free transport of DNA
to synovial fluid.
The presence of P. gingivalis in
synovial fluid supports the theory
on anti-CCP and citrullination.

C

i
t
a
t
i
o
n

:

J
o
u
r
n
a

l

o
f

O
r
a

l

i

M
c
r
o
b
o
o
g
y

i

l

2
0
1
2
,

4

:

1
1
8
2
9

-
D
O

I
:

1
0
.
3
4
0
2
/
j
o
m
.
v
4
0
.
1
1
8
2
9

i

(

p
a
g
e

n
u
m
b
e
r

n
o
t

f
o
r

c
i
t
a
t
i
o
n

p
u
r
p
o
s
e
)

7

Table 1 (Continued)

First author and
reference

General study design and

characteristics

Clinical data

Laboratory data

Findings

Conclusions/comments

Dissik et al. (63) Casecontrol clinical study.

RA defined by MD-HAQ,
DAS28, AAP classification of
periodontitis (6).
Subjects with RA 69 subjects
or osteoarthritis, 35 subjects.
RA  subjects were treated
with DMARDs, NSAIDs, tetra-
cyclines, or anti-TNF-a.
Animal study to assess P.
gingivalis, A. actinomycetem-
comitans-induced periodonti-
tis, and pristane-induced
arthritis (PIA) interaction in
mice.

Trombone et al.

(64)

Periodontal: PPD,
CAL,BOP, panora-
mic radiographs
(bone loss).

ESR, RA factor, anti-CCP anti-
body titers, serum CRP

Cytokines: ELISA assays: IL-1b,
IFN-g, IL-4,
IL-10, IL-17, TNF-a, RANKL/OPG,
MMP/s/TIMPs.
Serum titers to P. gingivalis and A.
actinomycetemcomitans.

Clinical evidence of
alveolar bone loss
and PPD.
Inflammatory cell
analysis ELISA
assays, rtPCR, for
bacterial assess-
ments and RNA
extractions from
periodontal tissues.

Mirrielees et al.

(65)

Cross-sectional, Casecontrol
study.
RA defined by ACR criteria
(53).
35 RA patients ranging in
age from 22 to 64 years were
enrolled and matched with 35
healthy controls and 35 sub-
jects with periodontitis.

Routine dental
(PPD, CAL, BOP)
and RA criteria
RA subjects
using DMARD
medication.

Concentrations of salivary IL-1b
and TNF-a assessed by Luminex
assay for IL-1b, and TNF-a, ELISA
for MMP-8.

Odds ratio of an association between RA
and having periodontitis 2.1 (95% CI:
1.1, 3.8, pB0.02).
Female gender and RA/periodontitis,
OR: 2.9 (95%CI: 1.4, 36.1, pB0.02).
Current smoking OR of RA and
periodontitis 2.9 (95%CI: 1.0, 8.5,
p0.06).

Higher severity PD in the genetically
inflammation prone acute inflammatory
reactivity maximum (AIRmax) mice strain
was associated with higher levels of
TNF-a, IL-1b, IL-17, matrix MMP-13, and
RANKL. Periodontitis/PIA co-induction
resulted in even higher levels of IL-1b,
IFN-g, IL-17, RANKL, and MMP-13 levels.
Periodontitis/PIA co-induction in AIRmin
strain did not alter the course of both
pathologies.
P. gingivalis or A. actinomycetemcomitans
infection did not further enhanced cytokine
counts but may cause more bone loss in
test animals.
Salivary levels of IL-1b and TNF-a were
significantly elevated in arthritis patients
not receiving anti-TNF-a antibody therapy
compared with arthritis patients receiving
anti-TNF-a therapy and healthy controls.
RA subjects had more BOP than
control subjects but less periodontitis.
IL-1b levels are higher in RA subjects
than in control subjects.

Moderate to severe periodontitis
was more frequently found in
RA patients and RF seroposi-
tive subjects or in subjects with
the anti-CCP antibody.
Female gender and smoking
habits are risk factors in the
RA/periodontitis
complex.
Animal model demonstrating as-
sociation between RA and peri-
odontitis with bone loss in test
animals after exp. arthritis.
Amplification of innate immune
responses (Th1/Th17) in RA-
induced mice.
The lack of added effects by
P. gingivalis and A. actinomyce-
temcomitans infection may be
explained by immune hyper
reactivity by experimentally
induced RA alone.

RA patients have higher levels
of periodontitis than healthy
controls.
Anti-TNF-a antibody-based dis-
ease-modifying therapy. Signifi-
cantly lowers salivary IL-1b and
TNF-a levels in RA. RA in the
absence of disease modifying
antirheumatic drugs appears to
influence levels of select salivary
biomarkers of
periodontitis.

R
h
e
u
m
a
t
o
d

i

a
r
t
h
r
i
t
i
s

a
n
d

p
e
r
i
o
d
o
n
t
i
t
i
s

G

.

R
u
t
g
e
r

P
e
r
s
s
o
n

Table 1 (Continued)

First author and
reference

General study design and

characteristics

Clinical data

Laboratory data

Findings

Conclusions/comments

Okada et al. (66) Casecontrol clinical study
RA defined by ACR criteria
(53).
AAP criteria periodontitis (6)
Purpose of study to assess if
serum levels of antibodies to
bacteria associated with peri-
odontitis may affect clinical
and laboratory profiles of RA80
RA and 38 matched healthy
control subjects.

Demographic data,
smoking status,
PPD, CAL, gingival
index.
The presence of
periodontitis was
defined as having
]1 periodontitis
site with
PD3 mm and
CAL]3 mm.

Serum levels of CRP; ELISA as-
says: anti-citrullinated peptide,
RA factor, IgG titers to A.actino-
mycetemcomitans, E. corrodens,
P. intermedia, P. gingivalis.

Ziebolz et al.

(67)

Case series, clinical study.
RA defined by ACR criteria (53)
and by DAS28.
Periodontal screening index
(CPITN/PSR).
To investigate periodontal and
microbiologic parameters in
patients with RA
66 subjects with RA were
studied.

RA factor, IL 1 genotype, CRP,
WBC, thrombocyte, neutrophil,
lymphocyte, and granulocyte
counts.
Microbiology by PCR: A. actino-
mycetemcomitans, P. gingivalis,
T. forsythia, T. denticola, P. micra,
P. intermedia, C. rectus, E. noda-
tum, E. corrodens, C. sputigena,
F. nucleatum. Detection threshold
102

Periodontal status,
periodontal screen-
ing index (PSR/
PSI), DMFT,
smoking habits,
Rheum tx.
(methotrexate, folic
acid, prednisolone,
leflunomide,
Ca carbonate
cholecalciferol).
Non-parametric
analysis controlling
for age, gender,
smoking, and RA
medication.

Sign lower titers in RA group to A.
actinomycetemcomitans and E. corrodens
but higher titers in RA subjects for P.
gingivalis IgG titers. Serum levels of anti-
CCP were higher in RA subjects. Serum
anti-P. gingivalis titers were correlated with
RA factor, probing depth, and clinical
attachment levels but not with anti CCP Ab
levels, BOP, or CRP.

E. corrodens and C. sputigena counts were
related to genotype and RA medication.
Correlation between RA factor and
E. nodatum (pB0.05), E. corrodens
(pB0.05) and Capnocytophaga sp.
(pB0.05) but not with P. gingivalis,
T. forsythia, T. denticola, F. nucleatum sp.
P. micra, or P. intermedia.

All RA subjects were on
medication that may have
affected the results.
Systemic administration of corti-
costeroids, antirheumatic drugs,
NSAIDs, TNF-a antagonist re-
duced signs of periodontitis.
Serum levels of anti-Pg IgG anti-
bodies were associated with RA
and may affect serum levels of RF
and periodontal condition in pa-
tients with RA.
No patients were periodontally
healthy.
Most patients with RA had
moderate-to-severe periodontitis
and presence pathogens
associated with periodontitis.
No association was found
between RA factor and period-
ontal status or microbiologic
parameters.

AAP, American Academy of Periodontology, ACRAmerican College of Rheumatology; BMI, body mass index; BOP, bleeding on probing; CAL, clinical attachment level; CRP, C-reactive
protein; DAS28, Disease Activity Score; ESR, erythrocyte sedimentation rate; OR, odds ratio; HAQhealth assessment questionnaire; PPD, probing pocket depth; PsA, psoriatic arthritis;
RA, rheumatoid arthritis; RF, rheumatoid factor; WBC, white blood cell counts; and abbreviations of bacteria names, i.e. P. gingivalis.

8(

p
a
g
e

n
u
m
b
e
r

n
o
t

f
o
r

c
i
t
a
t
i
o
n

p
u
r
p
o
s
e
)

C

i
t
a
t
i
o
n

:

J
o
u
r
n
a

l

o
f

O
r
a

l

i

M
c
r
o
b
o
o
g
y

i

l

2
0
1
2
,

4

:

1
1
8
2
9

-

D
O

I
:

1
0
.
3
4
0
2
/
j
o
m
.
v
4
0
.
1
1
8
2
9

i

and periodontitis assessed the presence of pathogens (by
PCR method) associated with periodontitis. The study
identified that, in bacterial samples from knee joints, such
bacteria were found in 100% of samples including one or
several species. Among the most prevalent species were
Prevotella intermedia, Treponema denticola, and P. gin-
givalis. Aggregatibacter actinomycetemcomitans was the
least commonly found microorganism. Findings from an
experimental study could also identify counts of A.
actinomycetemcomitans as a factor in bone loss in RA-
induced mice (64). Others have shown that anticitrullin
antibody levels were significantly higher in RA subjects
with advanced periodontitis than in RA subjects without
periodontitis (63). Thus, such studies suggest that key
pathogens in periodontitis are associated with RA. It
should be recognized that one study has failed to identify
pathogens in periodontitis as associated with RA (67) and
may be explained by confounders (i.e. smoking), medica-
tion, that all subjects had RA, or that periodontitis was
defined through a screening index.

Standard therapy in the treatment of
rheumatoid arthritis
This section, briefly presents medications used in the
treatment of RA. (The reader is referred to the pharma-
cological literature for detailed information.) The pri-
mary objectives in the treatment of patients with RA are
to reduce inflammation and to correct pathological
abnormalities to enhance quality of
life. Treatment
options include a variety of medications, efforts to reduce
joint stress, physical therapy, and surgical intervention.
Medications that are commonly used in RA treat-
ment
include non-steroidal anti-inflammatory agents
(NSAIDs  aspirin, ibuprofen, COX-2 inhibitor) corti-
costeroids, and disease modifying anti-rheumatic drugs
(DMARDs). In addition, injectable gold therapy (until
late 1990s), cyclosporine, diet, and climate-humidity
change are considered.

NSAID drugs can reduce acute inflammation and
decrease pain. Such medications alone do not change
the course of RA. Corticosteroids have both anti-
inflammatory and immune-regulatory activity but have
also been associated with several side effects (i.e. weight
gain and a Cushing-like appearance). Only DMARD
agents can change the course of RA but have a delayed
effect and differ from NSAIDs or cortisone therapy.
Currently, methotrexate is considered as the primary
DMARD agent in the management of RA. The effects
are related to effects on TNF-a pathways and the
inhibition of an enzyme involved in the metabolism of
folic acid. Methotrexate in higher dosages is also used in
cancer therapies. Hydroxychloroquine, a drug used in the
treatment of malaria appears to involve changes in
antigen presentation with effects on the innate immune
system and effective against RA. Medications with

Rheumatoid arthritis and periodontitis

anti-TNF-a inhibitors [i.e. Etanercept (Enbrelâ€ ), Inflix-
imab (Remicadeâ€ ), and Adalimumab (Humiraâ€ ] are
currently used in the treatment of RA. The risks of side
effects are mainly related to secondary infections.

Anti-inflammatory treatment of periodontitis has also
been proposed. Data suggest that lipoxin (LXA4) antag-
onizes P. gingivalis-induced cell activation dependent on
leukocyte-platelet interaction through downregulation of
CD11b/CD18 (68, 69). Animal studies have shown a
protective role for lipoxin,
limiting PMN recruitment
and PMN-mediated tissue
in relation to
P. gingivalis-induced infection (70). Recent data suggest
that administration of omega-3 polyunsaturated fatty
acids plus low-dose aspirin as an adjunctive treatment to
regenerative periodontal therapy provides additional clin-
ical benefits (70). Studies have also shown that using an
adjunctive subantimicrobial-dose of doxycycline in peri-
odontal therapy suppresses proinflammatory cytokines
and regulate the inflammatory response to therapy (71).

injury

Studies on the effects of treatment of
rheumatoid arthritis on periodontitis and the
effects of periodontal therapy on rheumatoid
arthritis conditions
There are several studies assessing the effects of RA
treatment on periodontal conditions as well as on the
impact of RA conditions following periodontal therapies.
The studies on RA treatment are related to DMARDs
whereas the periodontal intervention studies are based on
routine non-surgical periodontal debridement assessing
systemic effects. A summary of findings from select
studies is presented (Table 2).

Most studies on RA status as effects by non-surgical
routine periodontal therapy have used the American
Rheumatology College criteria from 1987 (51). It appears
that most study samples have been derived from clinics
providing care for RA subjects. History of DMARD or
other medication can be difficult to assess. Current
therapy, using DMARDs might have masked the impact
of RA on the development of periodontal. For example,
the extent of gingival inflammation and pseudo-pockets
may have been managed through DMARDS or other
anti-inflammatory agents used over longer periods of
time. It is also highly likely that extensive tooth extrac-
tions have been performed in RA subjects participating in
the reported intervention studies. For example,
the
NHANES III data reported by de Pablo et al. (57)
identified that 50% of RA subjects were edentulous.
Therefore, a large number of subjects with RA cannot be
assessed in relation to the association with periodontitis.
These edentulous subjects may represent severe cases with
periodontitis and RA. The fact that one study has
identified a high odds ratio for periodontitis and RA
should be carefully considered (59). It is important to
recognize that RA is not a highly prevalent disease

Citation: Journal of Oral Microbiology 2012, 4: 11829 - DOI: 10.3402/jom.v4i0.11829

(page number not for citation purpose)

9

(

p
a
g
e

1
0

n
u
m
b
e
r

n
o
t

f
o
r

c
i
t
a
t
i
o
n

p
u
r
p
o
s
e
)

C

i
t
a
t
i
o
n

:

J
o
u
r
n
a

l

o
f

O
r
a

l

i

M
c
r
o
b
o
o
g
y

i

l

2
0
1
2
,

4

:

1
1
8
2
9

-

D
O

I
:

1
0
.
3
4
0
2
/
j
o
m
.
v
4
0
.
1
1
8
2
9

i

G

.

R
u
t
g
e
r

P
e
r
s
s
o
n

Table 2. Selected studies assessing the effects of intervention in subjects with RA and/or periodontitis

Authors

Study conditions

Treatment

Treatment outcome

Al-Katma et al. (72)

Pers et al. (73)

Casecontrol intervention study (8 weeks)
RA defined by ACR criteria (53). Periodontitis

defined by AAP criteria (6)

To assess the effects of non-surgical periodontal

therapy on RA.
Casecontrol study; 40 subjects with RA
RA defined by ACR criteria (53).

Assessment of periodontal status BOP,

Seventeen subjects with RA receiving periodontal
treatment
12 subjects. with RA with no periodontal treatment.
***RA subjects on routine RA treatment (DMARDs).

RA activity assessed by DASH 28 and ESR.

58.8% in the test group and 16.7% in the period-

ontally untreated group demonstrated improved RA

scores.

20 subjects received infliximab/methotrexate every 6
weeks for ]22 months.
20 subjects (9 with periodontitis) were studied before

Plaque index and PPD were similar in both groups.
BOP increased in infliximab group (pB0.001).
Mean 0.4 mm decrease in CAL in infliximab-treated

PPD and CAL.

and after receiving 9nine infusions of infliximab.

group.

Miranda et al. (74)

Study purpose to assess the role of
anti-TNF-a on periodontal status.
Casecontrol study of 17 RA and 17 healthy
control age-, gender-, smoking-matched

subjects.
RA defined by ACR criteria (53).

No routine periodontal therapy was performed.

Clinical dental: plaque and gingival index, PPD, CAL,
GCF levels of elastase, IL-1b.
No dental treatment.
RA subjects were treated with prednisone (88.2%),

The study evaluated the effect of rheumatological

methotrexate (76.5%), NSAIDs (76.5%), and Sulfasala-

Mayer et al. (75)

treatment on periodontitis.
Casecontrol study.
RA defined by ACR criteria (53).

Periodontitis defined by AAP classification (6).
10 RA (RA) subjects, treated with with
infliximab, 10 RA (RA) untreated, 10 healthy
ctr. subjects.
To evaluate the influence of (TNF-a) therapy on the
clinical and immunologic parameters.

zine (23.5%)

Routine periodontal examintion
PI, BOP, PPD, CAL, GCF samples for TNF-a
(ELISA assay)

RA: data: DASH 28, ESR, RA factor, or anti-CCP Ab,

DMARDs use, number of erosive joints, time of RA,
smoking status.

Total amounts of IL-1b (pB0.01) and total elastase
higher in RA subjects (pB0.001).
Correlation between IL-1b and total elastase in the
RA group (r0.883; pB0.001) but not in the
control group.

PI similar by groups.
GI and BOP% higher in RA compared to RA and in
controls.
PPD and CAL less than in RA than in RA and in
controls
TNF-a overall corr. with CAL.
B GCF TNF-a in RA than in RA groups.
Suppression of proinflammatory cytokines may

reduce periodontal inflammation.

Ribeiro et al. (76)

Casecontrol study.
RA defined by ACR criteria (53).

Periodontitis defined by AAP.

Baseline to 3 months study including consecutive
subjects.

16 subjects received oral hygiene instructions,

supra-gingival cleaning.

26 subjects received full mouth debridement

To assess the effects of non-surgical periodontal

therapy on RA status.

HAQ, RF factor, ESR, drug therapy, routine periodontal

Subjects in the supra-gingival cleaning group had an

assessments (PPD and CAL).

increase in NSAID and prednisone compared to

baseline. No correlation between periodontal

parameters and RF.
Trends of RF decreased in both group after period-

ontal intervention, ESR and HAQ improved in the

subgingival debridement group, PPD and GI im-

proved in both groups but CAL only at advanced

sites in the group with subgingival

debridement.

Table 2 (Continued)

Authors

Pinho et al. (77)

C

i
t
a
t
i
o
n

:

J
o
u
r
n
a

l

o
f

O
r
a

l

i

M
c
r
o
b
o
o
g
y

i

l

Study conditions

Treatment

Treatment outcome

Casecontrol study in 75 subjects over 6 months.
RA defined by ACR criteria (53).
To assess the effects of therapy in RA and
RA subjects with periodontitis.

(DAS28), CRP, ESR, RF, alpha-1 acid glycoprotein, PD
(periodontal disease): ]2 teeth with CAL ]6 mm and
]1 tooth with PPD ]5 mm.
RA, PD, and periodontal treatment (TX).
RA, PD, and no periodontal treatment (TX).
RA, PD, and periodontal treatment (TX).

2
0
1
2
,

4

:

1
1
8
2
9

-
D
O

I
:

1
0
.
3
4
0
2
/
j
o
m
.
v
4
0
.
1
1
8
2
9

i

(

p
a
g
e

n
u
m
b
e
r

n
o
t

f
o
r

c
i
t
a
t
i
o
n

p
u
r
p
o
s
e
)

1
1

Ortiz et al. (78)

Queiroz-Junior et al.

(79)

Casecontrol study over 6 weeks.
RA defined by ACR criteria (53).
20 subjects with severe peridontitis and RA
(10 on DMARDs and 10 on anti-TNF-a) These
subjects received non-surgical periodontal

treatment.
20 RA subjects with similar periodontal condi-
tions (10 on DMARDs and 10 on anti-TNF-a).
These subjects. did not receive periodontal

treatment during the study.

To assess the effect of non-surgical periodontal

treatment on the signs and symptoms of RA in
patients treated with or without anti-TNF-a
medications.
Casecontrol animal study of chronic Ag-induced
arthritis (AIA) induced and treated with infliximab,
10 mg/kg, versus animals infected with A.a. JP2
clone (1109 CFU).
Chlorhexidine was applied in the mouth of mice

every 2 d after AIA until day 14.

Mice were killed at different time points

(7, 14, 30, 45, and 60 days postinfection).

Routine periodontal data: BOP, PI, PPD, CAL, number

of teeth.
RA data: VAS, ESR, DAS28, and TNF-a levels RF.

(RAPDTX): PPD reduced (pB0.01),% plaque
reduced (pB0.001). BOP reduction (p0.07), acute
phase laboratory data; NS.
(RAPDTX): NS changes in PD parameters;
ESR was reduced (pB0.001).
(RAPDTX): PPD,% plaque, BOP reduced
(pB0.001), systemic measures reduced
(pB0.001).
The relationship between RA and periodontitis

activity is unclear. Periodontal treatment in the

control of inflammation to avoid tooth extraction is

important.
No gender effect. No changes on periodontal

conditions in the two groups not receiving period-

ontal therapy.

No difference in ESR by periodontal conditions. In
both periodontal treatment groups, TNF-a de-
creased (pB0.001) and the number of symptomatic
joints (VAS) decreased (pB0.01). Periodontal treat-
ment groups showed sign. Decrease in BOP, PPD,
and gain of attachment.

Non-surgical periodontal therapy had a beneficial

effect on the signs and symptoms of RA, regardless

of the medications used to treat this condition. Anti-
TNF-a therapy without periodontal treatment had no
significant effect on the periodontal condition.

Morphometric evaluation of maxillae and histological

Induction of AIA resulted in severe alveolar

examination.
Knee joints of five mice per group were collected for

bone loss.
Alveolar bone loss in animals with AIA was similar to

histological evaluation.

Quantification of a neutrophil enzyme marker and a

macrophage enzyme marker. The concentrations of
IL-1b, IL-6, IL-17, IL-10, IFN-g, TNF-a, tumor growth
factor-b, RANKL, osteoprotegerin (OPG), and antic-
ollagen I total IgG in serum of mice were measured.

Assessment of CRP.

that induced by oral infection with A.actinomyce-

temcomitans.
Anti-TNF-a greatly improved AIA conditions but had
no effects on the number of bacteria. Treatment with

chlorhexidine improved periodontal conditions.

R
h
e
u
m
a
t
o
d

i

a
r
t
h
r
i
t
i
s

a
n
d

p
e
r
i
o
d
o
n
t
i
t
i
s

G. Rutger Persson

whereas the information on the prevalence of period-
ontitis is highly divergent (5). This makes it difficult to
interpret odds
study
populations.

ratio calculations

in different

Usually, the intervention studies have been performed
in subjects who use anti-inflammatory drugs for the
management of RA during the periodontal intervention.
Therefore, the additional effects of periodontal therapy to
reduce systemic inflammation may have been masked by
the efficacy of routine systemic medication to control for
inflammation (i.e. DMARDS). In one study, serum anti-
P. gingivalis titers were correlated with RA factor and
periodontal conditions, and treatment with DMARDS
improved periodontal conditions (66). This further sup-
ports the infectious relationship between periodontitis
and RA.

Two studies (70, 72) assessed the effects of anti-TNF-a
in the treatment of RA demonstrated that anti-TNF-a
therapy resulted in clinical benefits in regard to period-
ontal conditions. Presently, TNF-a therapy for the
treatment of periodontitis has only been assessed in
subjects with RA. Unpublished data through experiences
by the author of this review suggest that TNF-a therapy
in a patient with Morbus Crohn drastically improved
severe periodontal conditions. Anti-TNF-a therapy is,
however, also associated with serious adverse effects
(80, 81). At the present time, anti-TNF-a therapy or the
use of DMARDs in the sole management of periodontitis
cannot be advocated. Further information about the
impact of such medications could be important for the
current understanding and management of periodontitis.

Alternative medicine and nutrition in modulation
of inflammation in RA and periodontitis
that epigenetic changes
Accumulating data suggest
through the
regulation proinflammatory responses
through NFkB regulation affecting TNF-a may be
crucially involved in the pathology of RA and other
chronic inflammatory diseases (82). Data suggest that
oxidative stress is profound in RA and reactive oxygen
species play a causal role in RA. Medications used to
manage oxidant/antioxidant
imbalance may provide
alternatives in the treatment of RA (34, 83, 84). There
are merging data suggesting that dietary factors, such as
micronutrients and non-nutrient dietary components can
modify epigenetic marks (85). Thus, patients with RA
benefit from a diet rich in antioxidants, lactobacilli, and
fibers (86). In one pilot study, beneficial effects of an
antioxidant intervention on clinical parameters for RA
were identified (87). Recent data suggest that the admin-
istration of omega-3 fatty acids (omega-3 FA) reduces the
extent of swollen and tender joint in patients with active
RA (88). There is also emerging evidence that dietary
intake of polyphenols interferes with P. gingivalis, sug-
gesting that polyphenols in diet may be useful in the

management of periodontal disease (89). At this time,
there are no studies that specifically have addressed
the effects of polyphenols in patients with RA and
periodontitis.

Citrullination and heat chock proteins
P. gingivalis infection may through citrullination play a
significant role in RA. Although P. gingivalis hitherto is
the only bacterium that has been identified that expresses
endogenous citrullinated proteins, other factor may also
be associated with citrullination and through this
mechanism associated with RA (3640). Citrullinated
proteins can be found in keratin and filagrin in skin and,
i.e. oral mucosa. Citrullinated proteins are present in the
gingiva of patients with periodontitis (37). Such citrulli-
nated proteins are also involved in keratinocyte differ-
entiation. Physiological citrullination of myelin has been
linked to multiple sclerosis (90). Environmental and
genetic factors may induce autoimmunity to specific
citrullinated proteins (91).

The literature on the role of HSPs in autoimmune
disease and in periodontitis is extensive. HSPs linked to
P. gingivalis have hitherto not been considered in relation
to RA. HSP60 from P. gingivalis can trigger molecule
linking infectious periodontitis and autoimmune athero-
sclerosis (92). The progression of atherosclerosis can be
explained in terms of the immune response to bacterial
HSPs with bacterial HSPs are major antigenic determi-
nants during infection (93, 94). Current data also suggest
that HSPs are significant factors also in RA and related
to citrullination (95, 96).

Summary of review
There is historical evidence of a link between RA and
periodontitis. Although several studies have suggested an
association between RA and periodontitis well-controlled
large studies are needed to confirm these observations. As
for many other studies assessing the relationship between
periodontitis and diseases: i.e. diabetes mellitus, cardio-
vascular diseases, and adverse pregnancy outcomes,
studies have used different criteria for the definition of
periodontitis. Many studies have included few subjects.
Therefore, the lack of statistical power is of concern.
Most studies have included convenience cohorts and may
represent special populations with RA. Gender, age, and
smoking habits in subjects with RA and periodontitis are
other issues that are difficult to address in small samples.
This makes it almost impossible to compare and merge
study results and to draw firm conclusions.

Additional research both in regards to basic mecha-
nisms as well as clinical studies are needed before it can
be said that there are causative links between RA and
periodontitis. Nevertheless, some factors can be identi-
fied. In Fig. 1, factors that may be proven important for

12

(page number not for citation purpose)

Citation: Journal of Oral Microbiology 2012, 4: 11829 - DOI: 10.3402/jom.v4i0.11829

Rheumatoid arthritis and periodontitis

Fig. 1. Illustration of pathways of genetics, inï¬‚ammation, and infectious links between rheumatoid arthritis and periodontal
diseases.

further assessments of the association between RA and
periodontitis are presented.

information collected in preparation for the lecture on this topic at
the meeting in Bergen.

2)

1) Genetic factors are driving the host responses to
chronic diseases with a complex pathogenesis. Much
attention has been given to TNF-a, a proinflamma-
tory cytokine regulating a cascade of inflammatory
events in many disease including RA and period-
ontitis. Other diseases such as osteoporosis and
some cardiovascular diseases may share similar
genetic tracts to disease.
Infection has been identified as a primary etiology
for many diseases. The
abilities of
P. gingivalis as mentioned above through citrullina-
tion and the development of specific autoantibodies
may be a primary link between RA and period-
ontitis and explain not only the chronicity in RA but
also the chronicity of periodontitis. Whether other
oral bacteria associated with periodontitis are able
to induce citrullination has not yet been assessed. In
addition, P. gingivalis HSPs may trigger autoim-
mune responses.

specific

Acknowledgements

I appreciate the discussions and encouragement at the Meeting of
the Scandinavian Society of Periodontology in Bergen, Norway,
2011, to write this review. The review is based on the background

Conflict of interest and funding
The author declares no conflict of interest. No external
funding.

References

1. Sacks JJ, Luo YH, Helmick CG. Prevalence of speciï¬c types of
arthritis and other rheumatic conditions in the ambulatory
health care system in the United States, 20012005. Arthritis
Care Res 2010; 62: 4604.

2. Myasoedova E, Crowson CS, Kremers HM, Therneau TM,
Gabriel SE. Is the incidence of rheumatoid arthritis rising?
results from Olmsted County, Minnesota, 19552007. Arthritis
Rheum 2010; 62: 157682.

3. Silman AJ, Hochberg MC. Epidemiology of the rheumatic
diseases, second ed. New York: Oxford University Press; 2001.
4. Available from: http://www.rheumatology.org/practice/clinical/

classiï¬cation/ra/ra_2010.asp [cited 14 October 2011]

5. Page RC, Eke PI. Case deï¬nitions for use in population-based
surveillance of periodontitis. J Periodontol 2007; 78: 138799.
6. Armitage GC. Manual periodontal probing in supportive

periodontal treatment 2000. Periodontol 1996; 12: 339.
the effect of dental

7. Anonymous. An Evaluation of

focal

infection on health. JADA 1952; 42: 60997.

8. Desvarieux M, Demmer RT, Rundek T, Boden-Albala B, Jacobs
DR Jr, Sacco RL, et al. Periodontal microbiota and carotid
intima-media thickness:
the Oral Infections and Vascular
Disease Epidemiology Study (INVEST). Circulation 2005;
111: 57682.

Citation: Journal of Oral Microbiology 2012, 4: 11829 - DOI: 10.3402/jom.v4i0.11829

(page number not for citation purpose)

13

G. Rutger Persson

9. Hayashi C, Gudino CV, Gibson FC III, Genco CA. Review:
from oral
pathogen-induced inï¬‚ammation at sites distant
infection: bacterial persistence and induction of cell-speciï¬c
innate immune inï¬‚ammatory pathways. Mol Oral Microbiol
2010; 25: 30516.

10. Taylor BA, Toï¬‚er GH, Carey HM, Morel-Kopp MC, Philcox S,
Carter TR, et al. Full-mouth tooth extraction lowers systemic
inï¬‚ammatory and thrombotic markers of cardiovascular risk.
J Dent Res 2006; 85: 748.

11. Tonetti MS, Dâ€™Aiuto F, Nibali L, Donald A, Storry C, Parkar
M, et al. Treatment of periodontitis and endothelial function.
N Engl J Med 2007; 356: 91120.

12. Lindhe J, Okamoto H, Yoneyama T, Haffajee A, Socransky SS.
Longitudinal changes in periodontal disease in untreated
subjects. J Clin Periodontol 1989; 16: 66270.

13. Persson GR, DeRouen TA, Page RC. Relationship between
gingival crevicular ï¬‚uid levels of aspartate aminotransferase and
active tissue destruction in treated chronic periodontitis patients.
J Periodontal Res 1990; 25: 817.

14. Papapanou PN, Behle JH, Kebschull M, Celenti R, Wolf DL,
Handï¬eld M, et al. Subgingival bacterial colonization proï¬les
correlate with gingival tissue gene expression. BMC Microbiol
2009; 9: 221.

15. Paster BJ, Olsen I, Aas JA, Dewhirst FE. The breadth of
bacterial diversity in the human periodontal pocket and other
oral sites 2000. Periodontol 2006; 42: 807.

16. Preza D, Olsen I, Willumsen T, Grinde B, Paster BJ. Diversity
and site-speciï¬city of the oral microï¬‚ora in the elderly. Eur J
Clin Microbiol Infect Dis 2009; 28: 3340.

17. Fredericks DN, Relman DA. Sequence-based identiï¬cation of
microbial pathogens: a reconsideration of Kochâ€™s postulates.
Clin Microbiol Rev 1996; 9: 1833.

18. Holt SC, Ebersole J, Felton J, Brunsvold M, Kornman KS.
Implantation of Bacteroides gingivalis in nonhuman primates
initiates progression of periodontitis. Science 1988; 239: 557.

19. Persson GR, Engel D, Whitney C, Darveau R, Weinberg A,
Brunsvold M, et al. Immunization against Porphyromonas
gingivalis inhibits progression of experimental periodontitis in
nonhuman primates. Infect Immun 1994; 62: 102631.

20. Moritz AJ, Cappelli D, Lantz MS, Holt SC, Ebersole JL.
Immunization with Porphyromonas gingivalis cysteine protease:
effects on experimental gingivitis and ligature-induced period-
ontitis in Macaca fascicularis. J Periodontol 1998; 69: 68697.
21. Page RC, Lantz MS, Darveau R, Jeffcoat M, Mancl L, Houston
L, et al. Immunization of Macaca fascicularis against experi-
mental periodontitis using a vaccine containing cysteine pro-
teases puriï¬ed from Porphyromonas gingivalis. Oral Microbiol
Immunol 2007; 22: 1628.

22. Strauss J, Kaplan GG, Beck PL, Rioux K, Panaccione R,
Devinney R, et al. Invasive potential of gut mucosa-derived
Fusobacterium nucleatum positively correlates with IBD status of
the host. Inï¬‚amm Bowel Dis 2011; 17: 19718.

23. Brook I. Role of anaerobic bacteria in infections following
intubation, or the use of ventilatory tubes in

tracheostomy,
children. Ann Otol Rhinol Laryngol 2004; 113: 8304.

24. Nikolaitchouk N, Andersch B, Falsen E, StroÂ¨ mbeck L,
Mattsby-Baltzer I. The lower genital tract microbiota in relation
to cytokine-, SLPI- and endotoxin levels: application of checkerboard
DNA-DNA hybridization (CDH). APMIS 2008; 116: 26377.
25. Persson R, Hitti J, Verhelst R, Vaneechoutte M, Persson R,
Hirschi R, et al. The vaginal microï¬‚ora in relation to gingivitis.
BMC Infect Dis 2009; 9: 6.

26. Cotsapas C, Voight BF, Rossin E, Lage K, Neale BM, Wallace
C, et al. FOCiS Network of Consortia. Pervasive sharing of
genetic effects in autoimmune disease. PLoS Genet 2011; 7: e1002254.

27. SchaÂ¨fer AS, Jepsen S, Loos BG. Periodontal genetics: a decade
of genetic association studies mandates better study designs. J
Clin Periodontol 2011; 38: 1037.

28. Nakaoka H, Cui T, Tajima A, Oka A, Mitsunaga S, Kashiwase
K, et al. A systems genetics approach provides a bridge from
discovered genetic variants to biological pathways in rheuma-
toid arthritis. PLoS One 2011; 6: e25389.

29. RodrÄ±Â´guez-RodrÄ±Â´guez L, Lamas JR, VaradeÂ´ J, Tornero-Esteban
P, Abasolo L, de la Concha EG, et al. Combined inï¬‚uence of
genetic and environmental factors in age of rheumatoid arthritis
onset. Rheumatol Int 2011. doi: 10.1007/s00296-011-2090-9.

30. Costenbader KH, Prescott J, Zee RY, De Vivo I. Immunosenes-
cence and rheumatoid arthritis: does telomere shortening
predict impending disease? Autoimmun Rev 2011; 10: 56973.
31. Ospelt C, Reedquist KA, Gay S, Tak PP. Inï¬‚ammatory
memories: is epigenetics the missing link to persistent stromal
cell activation in rheumatoid arthritis? Autoimmun Rev 2011;
10: 51924.

32. Gomez RS, Dutra WO, Moreira PR. Epigenetics and period-
ontal disease: future perspectives. Inï¬‚amm Res 2009; 58: 6259.
33. Grabiec AM, Reedquist KA. Histone deacetylases in RA:
epigenetics and epiphenomena. Arthritis Res Ther 2010; 12: 142.
34. McCall CE, Yoza B, Liu T, El Gazzar M. Gene-speciï¬c
epigenetic regulation in serious infections with systemic inï¬‚am-
mation. J Innate Immun 2010; 2: 395405.

35. RantapaÂ¨aÂ¨-Dahlqvist S, de Jong BA, Berglin E, Hallmans G,
Wadell G, Stenlund H, et al. Antibodies against cyclic citrulli-
nated peptide and IgA rheumatoid factor predict the develop-
ment of rheumatoid arthritis. Arthritis Rheum 2003; 48: 27419.
36. Rosenstein ED, Greenwald RA, Kushner LJ, Weissmann G.
Hypothesis: the humoral
immune response to oral bacteria
provides a stimulus for the development of rheumatoid arthritis.
Inï¬‚ammation 2004; 28: 3118.

37. Wegner N, Wait R, Sroka A, Eick S, Nguyen KA, Lundberg K,
et al. Peptidylarginine deiminase from Porphyromonas gingivalis
citrullinates human ï¬brinogen and a-enolase: implications for
autoimmunity in rheumatoid arthritis. Arthritis Rheum 2010;
62: 266272.

38. Lundberg K, Wegner N, Yucel-Lindberg T, Venables PJ. Period-
ontitis in RA*the citrullinated enolase connection. Nat Rev
Rheumatol 2010; 6: 72730.

39. Kinloch A, Lundberg K, Wait R, Wegner N, Lim NH, Zendman
AJ, et al. Synovial ï¬‚uid is a site of citrullination of autoantigens
in inï¬‚ammatory arthritis. Arthritis Rheum 2008; 58: 228795.
40. Lundberg K, Kinloch A, Fisher BA, Wegner N, Wait R, Charles
P, et al. Antibodies to citrullinated alpha-enolase peptide 1 are
speciï¬c for rheumatoid arthritis and cross-react with bacterial
enolase. Arthritis Rheum 2008; 58: 300919.

41. Nigrovic PA, Lee DM. Synovial mast cells: role in acute and

chronic arthritis. Immunol Rev 2007; 217: 1937.

42. Vandooren B, Cantaert T, Noordenbos T, Tak PP, Baeten D.
The abundant synovial expression of the RANK/RANKL/
Osteoprotegerin system in peripheral spondylarthritis is par-
tially disconnected from inï¬‚ammation. Arthritis Rheum 2008;
58: 71829.

43. Wang Q, Ma Y, Liu D, Zhang L, Wei W. The roles of B cells and
their interactions with ï¬broblast-like synoviocytes in the patho-
genesis of rheumatoid arthritis. Int Arch Allergy Immunol 2011;
155: 20511.

44. Choy E. New biologics for rheumatoid arthritis. J R Coll

Physicians Edinb 2011; 41: 2347.

45. Astry B, Harberts E, Moudgil KD. A cytokine-centric view
of the pathogenesis and treatment of autoimmune arthritis. J
Interferon Cytokine Res. 2011; 31: 92740.

46. Romas E, Gillespie MT, Martin TJ. Involvement of receptor
activator of NFkappaB ligand and tumor necrosis factor-alpha

14

(page number not for citation purpose)

Citation: Journal of Oral Microbiology 2012, 4: 11829 - DOI: 10.3402/jom.v4i0.11829

in bone destruction in rheumatoid arthritis. Bone 2002; 30:
3406.

47. HernaÂ´ndez M, Dutzan N, GarcÄ±Â´a-Sesnich J, Abusleme L,
Dezerega A, Silva N, et al. Host-pathogen interactions in
progressive chronic periodontitis. J Dent Res 2011; 90: 116470.
48. Orita S, Koshi T, Mitsuka T, Miyagi M, Inoue G, Arai G, et al.
Associations between proinï¬‚ammatory cytokines in the synovial
ï¬‚uid and radiographic grading and pain-related scores in 47
consecutive patients with osteoarthritis of the knee. BMC
Musculoskelet Disord 2011; 12: 144.

49. Preshaw PM, Taylor JJ. How has research into cytokine
interactions and their role in driving immune responses im-
pacted our understanding of periodontitis? J Clin Periodontol
2011; 38: 6084.

50. Fagundes JA, Monoo LD, EuzeÂ´bio Alves VT, Pannuti CM,
Cortelli SC, Cortelli JR, et al. Porphyromonas gingivalis is
associated with protease-activated receptor-2 up-regulation in
chronic periodontitis. J Periodontol 2011; 82: 1596601.

51. Belibasakis GN, Bostanci N, Reddi D. Regulation of protease-
activated receptor-2 expression in gingival ï¬broblasts and
Jurkat T cells by Porphyromonas gingivalis. Cell Biol Int 2010;
34: 28792.

52. Mercado RB, Marshall RI, Klestov AC, Bartold PM. Relation-
ship between rheumatoid arthritis and periodontitis. J Period-
ontol 2001; 72: 77987.

53. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF,
Cooper NS, et al. The American Rheumatism Association 1987
revised criteria for the classiï¬cation of rheumatoid arthritis.
Arthritis Rheum 1988; 31: 31524.

54. Moen K, Brun JG, Valen M, Skartveit L, Eribe EK, Olsen I,
et al. Synovial inï¬‚ammation in active rheumatoid arthritis and
psoriatic arthritis facilitates trapping of a variety of oral
bacterial DNAs. Clin Exp Rheumatol 2006; 24: 65663.

55. Kobayashi T, Ito S, Kuroda T, Yamamoto K, Sugita N,
Narita I, et al. The interleukin-1 and Fcgamma receptor gene
polymorphisms in Japanese patients with rheumatoid arthritis
and periodontitis. J Periodontol 2007; 78: 23118.

56. Leksell E, Ernberg M, Magnusson B, Hedenberg-Magnusson B.
Intraoral condition in children with juvenile idiopathic arthritis
compared to controls. Int J Paediatr Dent 2008; 18: 42333.

57. de Pablo P, Dietrich T, McAlindon TE. Association of period-
ontal disease and tooth loss with rheumatoid arthritis in the US
population. J Rheumatol 2008; 35: 706.

58. Nilsson M, Kopp S. Gingivitis and periodontitis are related
to repeated high levels of circulating tumor necrosis factor-alpha
in patients with rheumatoid arthritis. J Periodontol 2008; 79:
168996.

59. Pischon N, Pischon T, KroÂ¨ger J, GuÂ¨ lmez E, Kleber BM,
Bernimoulin JP, et al. Association among rheumatoid arthritis,
oral hygiene, and periodontitis. J Periodontol 2008; 79: 97986.
60. Prevoo ML, vanâ€™t Hof MA, Kuper HH, van Leeuwen MA, van
de Putte LB, van Riel PL. Modiï¬ed disease activity scores that
include twenty-eight-joint counts. Development and validation
in a prospective longitudinal study of patients with rheumatoid
arthritis. Arthritis Rheum 1995; 38: 448.

61. BiyikogË˜lu B, Buduneli N, KardesÂ¸ler L, Aksu K, Pitkala M,
Sorsa T. Gingival crevicular ï¬‚uid MMP-8 and -13 and TIMP-1
levels in patients with rheumatoid arthritis and inï¬‚ammatory
periodontal disease. J Periodontol 2009; 80: 130714.

62. Martinez-Martinez RE, Abud-Mendoza C, PatinËœ o-Marin N,
Rizo-RodrÄ±Â´guez JC, Little JW, Loyola-RodrÄ±Â´guez JP. Detection
of periodontal bacterial DNA in serum and synovial ï¬‚uid in
refractory rheumatoid arthritis patients. J Clin Periodontol
2009; 36: 100410.

Rheumatoid arthritis and periodontitis

63. Dissick A, Redman RS, Jones M, Rangan BV, Reimold A,
Grifï¬ths GR, et al. Association of periodontitis with rheuma-
toid arthritis: a pilot study. J Periodontol 2010; 81: 22330.

64. Trombone AP, Claudino M, Colavite P, de Assis GF, Avila-
Campos MJ, Silva JS, et al. Periodontitis and arthritis interac-
tion in mice involves a shared hyper-inï¬‚ammatory genotype and
functional immunological interferences. Genes Immun 2010; 11:
47989.

65. Mirrielees J, Crofford LJ, Lin Y, Kryscio RJ, Dawson DR III,
Ebersole JL, et al. Rheumatoid arthritis and salivary biomarkers
of periodontal disease. J Clin Periodontol 2010; 37: 106874.

66. Okada M, Kobayashi T, Ito S, Yokoyama T, Komatsu Y, Abe A,
et al. Antibody responses to periodontopathic bacteria in
relation to rheumatoid arthritis in Japanese adults. J Period-
ontol 2011; 82: 143341.

67. Ziebolz D, Pabel SO, Lange K, Krohn-Grimberghe B, Hor-
necker E, Mausberg RF. Clinical periodontal and microbiologic
parameters in patients with rheumatoid arthritis. J Periodontol
2011; 82: 14242.

68. BoÂ¨ rgeson E, LoÂ¨ nn J, BergstroÂ¨ m I, Brodin VP, RamstroÂ¨ m S,
Nayeri F, et al. Lipoxin A4 inhibits Porphyromonas gingivalis-
induced aggregation and reactive oxygen species production by
modulating neutrophil-platelet interaction and CD11b expres-
sion. Infect Immun 2011; 79: 148997.

inhibit

leukocyte recruitment

69. Pouliot M, Clish CB, Petasis NA, Van Dyke TE, Serhan CN.
to
Lipoxin A(4) analogues
Porphyromonas gingivalis: a role for cyclooxygenase-2 and
lipoxins in periodontal disease. Biochemistry 2000; 39: 47618.
70. Elkhouli AM. The efï¬cacy of host response modulation therapy
(omega-3 plus low-dose aspirin) as an adjunctive treatment of
chronic periodontitis (clinical and biochemical study). J Period-
ontal Res 2011; 46: 2618.

71. Emingil G, GuÂ¨ rkan A, Atilla G, Kantarci A. Subantimicrobial-
dose doxycycline and cytokine-chemokine levels in gingival
crevicular ï¬‚uid. J Periodontol 2011; 82: 45261.

72. Al-Katma MK, Bissada NF, Bordeaux JM, Sue J, Askari AD.
Control of periodontal infection reduces the severity of active
rheumatoid arthritis. J Clin Rheumatol 2007; 13: 1347.

73. Pers JO, Saraux A, Pierre R, Youinou P. Anti-TNF-alpha
immunotherapy is associated with increased gingival inï¬‚amma-
tion without clinical attachment loss in subjects with rheuma-
toid arthritis. J Periodontol 2008; 79: 164551.

74. Miranda LA, IslabaËœo AG, Fischer RG, Figueredo CM, Opper-
mann RV, Gustafsson A. Decreased interleukin-1beta and
elastase in the gingival crevicular ï¬‚uid of individuals undergoing
anti-inï¬‚ammatory treatment for rheumatoid arthritis. J Period-
ontol 2007; 78: 16129.

75. Mayer Y, Balbir-Gurman A, Machtei EE. Anti-tumor necrosis
factor-alpha therapy and periodontal parameters in patients
with rheumatoid arthritis. J Periodontol 2009; 80: 141420.

76. Ribeiro J, LeaËœo A, Novaes AB. Periodontal

infection as a
possible severity factor for rheumatoid arthritis. J Clin Period-
ontol 2005; 32: 4126.

77. Pinho Mde N, Oliveira RD, Novaes AB Jr, Voltarelli JC.
Relationship between periodontitis and rheumatoid arthritis
and the effect of non-surgical periodontal treatment. Braz Dent
J 2009; 20: 35564.

78. Ortiz P, Bissada NF, Palomo L, Han YW, Al-Zahrani MS,
Panneerselvam A, et al. Periodontal therapy reduces the severity
of active rheumatoid arthritis in patients treated with or without
tumor necrosis factor inhibitors. J Periodontol 2009; 80: 53540.
79. Queiroz-Junior CM, Madeira MF, Coelho FM, Costa VV,
Bessoni RL, Sousa LF, et al. Experimental arthritis triggers
periodontal disease in mice: involvement of TNF-{alpha} and
the oral microbiota. J Immunol 2011; 187: 382130.

Citation: Journal of Oral Microbiology 2012, 4: 11829 - DOI: 10.3402/jom.v4i0.11829

(page number not for citation purpose)

15

G. Rutger Persson

80. Strangfeld A, Eveslage M, Schneider M, Bergerhausen HJ,
Klopsch T, Zink A, Listing J. Treatment beneï¬t or survival of
the ï¬ttest: what drives the time-dependent decrease in serious
infection rates under TNF inhibition and what does this imply
for the individual patient? Ann Rheum Dis. 2011; 70: 191420.
81. Komano Y, Tanaka M, Nanki T, Koike R, Sakai R, Kameda H,
et al. REAL Study Group. Incidence and risk factors for serious
infection in patients with rheumatoid arthritis treated with
tumor necrosis factor inhibitors: a report from the Registry of
Japanese Rheumatoid Arthritis Patients for Longterm Safety. J
Rheumatol 2011; 38: 125864.

82. Hassan SZ, Gheita TA, Kenawy SA, Fahim AT, El-Sorougy IM,
Abdou MS. Oxidative stress in systemic lupus erythematosus
and rheumatoid arthritis patients:
relationship to disease
manifestations and activity. Int J Rheum Dis 2011; 14: 32531.
83. Park MK, Park JS, Cho ML, Oh HJ, Heo YJ, Woo YJ, et al.
(GSPE) differentially
Grape seed proanthocyanidin extract
regulates Foxp3() regulatory and IL-17() pathogenic T cell
in autoimmune arthritis. Immunol Lett 2011; 135: 508.

84. Calder PC, Albers R, Antoine JM, Blum S, Bourdet-Sicard R,
Ferns GA, et al. Inï¬‚ammatory disease processes and interac-
tions with nutrition. Br J Nutr 2009; 101: S145.

85. McKay JA, Mathers JC. Diet induced epigenetic changes and
their implications for health. Acta Physiol (Oxf) 2011; 202:
10318.

86. HaÂ¨nninen, Kaartinen K, Rauma AL, Nenonen M, ToÂ¨ rroÂ¨ nen R,
HaÂ¨kkinen AS, et al. Antioxidants in vegan diet and rheumatic
disorders. Toxicology 2000; 155: 4553.

87. van Vugt RM, Rijken PJ, Rietveld AG, van Vugt AC, Dijkmans
BA. Antioxidant intervention in rheumatoid arthritis: results of
an open pilot study. Clin Rheumatol 2008; 27: 7715.

88. Bahadori B, Uitz E, Thonhofer R, Trummer M, Pestemer-Lach
I, McCarty M, et al. omega-3 Fatty acids infusions as adjuvant
therapy in rheumatoid arthritis. J Parenter Enteral Nutr 2010;
34: 1515.

89. Bonifait L, Grenier D. Cranberry polyphenols: potential
beneï¬ts for dental caries and periodontal disease. J Can Dent
Assoc 2010; 76: a130.

90. Oguz KK, Kurne A, Aksu AO, Karabulut E, Serdaroglu A,
Teber S, et al. Assessment of citrullinated myelin by 1H-MR
spectroscopy in early-onset multiple sclerosis. Am J Neuroradiol
2009; 30: 71621.

91. Wegner N, Lundberg K, Kinloch A, Fisher B, MalmstroÂ¨ m V,
Feldmann M, et al. Autoimmunity to speciï¬c citrullinated
proteins gives the ï¬rst clues to the etiology of rheumatoid
arthritis. Immunol Rev 2010; 233: 3454.

92. Sweier DG, Shelburne PS, Giannobile WV, Kinney JS, Lopatin
DE, Shelburne CE. Immunoglobulin G (IgG) class, but Not IgA
or IgM, antibodies to peptides of the Porphyromonas gingivalis
chaperone HtpG predict health in subjects with periodontitis by
a ï¬‚uorescence enzyme-linked immunosorbent assay. Clin Vac-
cine Immunol 2009; 16: 176673.

93. Choi J, Lee SY, Kim K, Choi BK. Identiï¬cation of immunor-
eactive epitopes of the Porphyromonas gingivalis heat shock
protein in periodontitis and atherosclerosis. J Periodontal Res
2011; 46: 2405.

94. Seymour GJ, Ford PJ, Cullinan MP, Leishman S, Yamazaki K.
infections and systemic

Relationship between periodontal
disease. Clin Microbiol Infect 2007; 13: 310.

95. Wu CT, Ou LS, Yeh KW, Lee WI, Huang JL. Serum heat shock
remission of ï¬‚are-up in juvenile

protein 60 can predict
idiopathic arthritis. Clin Rheumatol 2011; 30: 95965.

96. BodnaÂ´r N, Szekanecz Z, ProhaÂ´szka Z, KemeÂ´ny-Beke A,
NeÂ´methneÂ´-Gyurcsik Z, GulyaÂ´s K, et al. Anti-mutated citrulli-
nated vimentin (anti-MCV) and anti-65kDa heat shock protein
(anti-hsp65): New biomarkers in ankylosing spondylitis. Joint
Bone Spine 2012; 79: 636.

*G. Rutger Persson
Oral Health Sciences
University of Kristianstad
Kristianstad, Sweden
Email: rutger.persson@hkr.se

16

(page number not for citation purpose)

Citation: Journal of Oral Microbiology 2012, 4: 11829 - DOI: 10.3402/jom.v4i0.11829

